ProfileGDS5678 / 1429614_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 73% 72% 74% 74% 72% 67% 73% 74% 77% 71% 73% 72% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.604472
GSM967853U87-EV human glioblastoma xenograft - Control 24.7294873
GSM967854U87-EV human glioblastoma xenograft - Control 34.5319772
GSM967855U87-EV human glioblastoma xenograft - Control 44.9356174
GSM967856U87-EV human glioblastoma xenograft - Control 54.9053774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5303472
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.129567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.675973
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8188374
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2360377
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4871571
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7849573
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5247672
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5193472